CA Final · Financial Reporting · Ind AS 27 Separate Financial Statements
Lakshya Holdings Ltd elects Ind AS 109 for investments in subsidiaries in its SFS, so they are held at fair value. One such investment, Orion Tech Ltd, becomes held for sale at year end. Carrying amount (fair value) is ₹50 crore; fair value less costs to sell is ₹48 crore. What is the SFS treatment?
The investment stays at ₹50 crore. For investments accounted for under Ind AS 109, classification as held for sale does not change their measurement; only investments carried at cost are accounted for under Ind AS 105.
- AWrite down to ₹48 crore through profit or loss under Ind AS 105
- BWrite down to ₹48 crore through other comprehensive income
- CRetain ₹50 crore, as measurement under Ind AS 109 is not changedCorrect
- DTransfer to cost basis at ₹50 crore and then apply Ind AS 105
Explanation
Ind AS 27 states that the measurement of investments accounted for under Ind AS 109 is not changed when they are classified as held for sale. Only cost-based investments move to Ind AS 105 measurement. So the ₹2 crore write-down in option A is wrong.
Did you get it right without looking?
One question tells you little. A timed set on Ind AS 27 Separate Financial Statements shows your real accuracy, how long you take and where you lose marks.
More Ind AS 27 Separate Financial Statements questions
- Meghna Ltd carries its investment in its subsidiary Pragati Ltd at cost in its separate financial statements, at ₹40 crore. At the reporting…
- Sagar Foods Ltd is a parent that is required, under paragraph 31 of Ind AS 110, to measure its investment in a subsidiary at fair value thro…
- Kaveri Industries Ltd holds investments in three subsidiaries, A Ltd, B Ltd and C Ltd, and two associates, D Ltd and E Ltd. In its separate …
- Vertex Holdings Ltd measures its investments in subsidiaries in separate financial statements in accordance with Ind AS 109 (fair value thro…
- Rudra Ltd has an associate, Sagar Ltd, and elects under Ind AS 28 to measure this investment at fair value through profit or loss under Ind …
- Meridian Pharma Ltd carries its investment in a subsidiary, Sahyadri Labs Ltd, at cost in its separate financial statements. At the reportin…